Literature DB >> 31655776

Hypertension and Acromegaly.

Soraya Puglisi1, Massimo Terzolo2.   

Abstract

Hypertension is one of the most frequent complications in acromegaly, with a median frequency of 33.6% (range, 11%-54.7%). Although the pathogenesis has not been fully elucidated, it probably results from concomitant factors leading to expansion of extracellular fluid volume, increase of peripheral vascular resistance, and development of sleep apnea syndrome. Because the effect of normalization of growth hormone and insulinlike growth factor 1 excess on blood pressure levels is unclear, an early diagnosis of hypertension and prompt antihypertensive treatment are eagerly recommended, regardless of the specific treatment of the acromegalic disease and the level of biochemical control attained.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antihypertensive treatment; Blood pressure; Cardiovascular complication; Cardiovascular risk; Mortality; Pathogenesis; Prevalence; Sleep apnea

Mesh:

Substances:

Year:  2019        PMID: 31655776     DOI: 10.1016/j.ecl.2019.08.008

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  6 in total

1.  Body Composition in Acromegaly According to Disease Activity - Performance of Dual X-Ray Absorptiometry and Multifrequency Bioelectrical Impedance Analysis.

Authors:  Aline Alves Lopes; Luciano Albuquerque; Mayara Fontes; Daniella Rego; Francisco Bandeira
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-18       Impact factor: 6.055

2.  Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence.

Authors:  Salvatore Giovinazzo; Soraya Puglisi; Oana R Cotta; Angela Alibrandi; Tommaso Aversa; Laura Cannavò; Francesco Ferraù; Salvatore Cannavò
Journal:  Pituitary       Date:  2021-01-19       Impact factor: 4.107

3.  Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study.

Authors:  Giulia Carosi; Alessandra Mangone; Elisa Sala; Giulia Del Sindaco; Roberta Mungari; Arianna Cremaschi; Emanuele Ferrante; Maura Arosio; Giovanna Mantovani
Journal:  Eur J Endocrinol       Date:  2021-07-01       Impact factor: 6.664

Review 4.  Advances in Research on the Cardiovascular Complications of Acromegaly.

Authors:  Han Yang; Huiwen Tan; He Huang; Jianwei Li
Journal:  Front Oncol       Date:  2021-04-02       Impact factor: 6.244

5.  Prevalence of Comorbidities among Patients with Acromegaly.

Authors:  Sajjad Ali Khan; Nanik Ram; Muhammad Qamar Masood; Najmul Islam
Journal:  Pak J Med Sci       Date:  2021 Nov-Dec       Impact factor: 1.088

Review 6.  Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.

Authors:  Soraya Puglisi; Francesco Ferraù; Marta Ragonese; Federica Spagnolo; Salvatore Cannavò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-06       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.